Appendix 3: Competing interests of participants of the Third Canadian Consensus Conference on Diagnosis and Treatment of Dementia*

- **Dr. Peter Bailey** has received honoraria from Pfizer, Janssen-Ortho and Novartis as a continuing medical education (CME) lecturer.
- **Dr. B. Lynn Beattie** has served on the advisory boards of Novartis and Janssen-Ortho; has received speaker fees from Novartis, Pfizer Canada and Janssen-Ortho; and has received research grants from Pfizer Canada and Janssen-Ortho.
- **Dr. Sandra Black** has received research grants from Eisai, Pfizer, Janssen-Ortho and Novartis; honoraria from Eisai, Pfizer, Janssen-Ortho, Novartis and Lundbeck as a CME lecturer; and consultancy fees from Eisai, Pfizer, Janssen-Ortho, Novartis, Lundbeck and Myriad. She has been a trial investigator for Sanofi-Aventis.
- **Dr. Christian Bocti** has served as a consultant to Janssen-Ortho and Pfizer; and has received speaker fees for CME presentations from these companies as well as Novartis and Merck-Frosst.
- **Dr. Rémi Bouchard** has served on the advisory boards of and as a consultant to Pfizer Canada, Novartis, Janssen-Ortho and Lundbeck Canada; and has received speaker and lecture fees as well as research grants from these companies.
- **Dr. Anna Byszewski** has received unrestricted educational grants from Janssen-Ortho, Pfizer and Novartis.
- **Dr. Howard Chertkow** has served on the advisory boards of Pfizer Canada, Neurochem and Lundbeck Canada; has received speaker fees from Pfizer Canada and Lundbeck Canada; has received research grants from Pfizer Canada; and has served as a consultant to NeuroTrax.
- **Dr. Tiffany Chow** has served on the speaker's bureaus of Janssen-Ortho and Novartis and as a consultant to Janssen-Ortho. She has received a grant for an investigator-initiated trial from Lundbeck Canada
- Dr. Howard Feldman has received research grant support or participated in clinical trials funded by Pfizer, Eisai, Janssen-Ortho, AstraZeneca, Sanofi-Aventis, Ono, GlaxoSmithKline, Myriad and Eli Lilly; has served as a consultant to Pfizer Canada, Eisai, Ono, Janssen-Ortho, AstraZeneca, Sanofi-Aventis, GlaxoSmithKline, Novartis, Servier, Myriad, Targacept, Lundbeck, Nestle, Merck Serono and Axonyx; and has received speaker honoraria for CME lectures from Pfizer, Eisai, Janssen-Ortho, Novartis, Shire, AstraZeneca and Forest.
- **Dr. John D. Fisk** has served as a consultant to Sanofi-Aventis, Biogen-Idec, Bayer, Novartis, AstraZeneca, Bristol-Myers Squibb, Roche and Teva Neuroscience.
- **Dr. Morris Freedman** has served on the advisory boards of Pfizer, Janssen-Ortho, Novartis and Wyeth, has received speaker fees from Pfizer, Janssen-Ortho, Novartis and Lundbeck Canada and has received research grants from Pfizer, Lundbeck Canada and Eli Lilly.
- **Dr. Angela Garcia** has served as a consultant and adviser to Janssen-Ortho, Pfizer Canada, Novartis and Lundbeck International.
- Dr. Serge Gauthier has served as a consultant to Pfizer Canada, Janssen-Ortho, Novartis, Lundbeck Canada, Neurochem, GlaxoSmithKline and Sanofi-Aventis; has received lecture fees from Pfizer Canada, Janssen-Ortho, Novartis and Lundbeck Canada; and has received research grants from Pfizer Canada, Janssen-Ortho, Novartis, Lundbeck Canada, Neurochem, GlaxoSmithKline, and Sanofi-Aventis.
- **Dr. Nathan Herrmann** has served on the advisory boards of Janssen-Ortho, Pfizer Canada and Lundbeck Canada; has served as a consultant to Janssen-Ortho, Novartis and Lundbeck Canada; has received speaker fees from Janssen-Ortho, Pfizer Canada, Novartis, Lundbeck Canada, Eli Lilly, Organon and AstraZeneca; and has received research grants from Janssen-Ortho, Lundbeck Canada and Neurochem.

- **Dr. David B. Hogan** has served as a primary investigator at a study site for a dementia study funded by Neurochem, Pfizer Canada and Janssen-Ortho; and has received speaker fees and honoraria for CME presentations from Janssen-Ortho and Pfizer Canada.
- **Dr. Robin Hsiung** has received speaker fees from Novartis; and has served as a site investigator on clinical trials funded by Pfizer and Ono Pharmaceuticals.
- **Dr. Andrew Kertesz** has served on the advisory boards of Pfizer Canada and Novartis; and has received speaker fees from Janssen-Ortho, Novartis and Lundbeck Canada.
- **Dr. Krista Lanctot** has served as a consultant to Pfizer Canada, Abbott Laboratories, Janssen-Ortho and Wyeth; has received speaker fees from Pfizer Canada; and has received research grants from Pfizer Canada, Abbott Laboratories, Janssen Ortho, Lundbeck Canada and Wyeth.
- **Dr. Gabriel C. Léger** has received honoraria from Janssen-Ortho, Novartis and Pfizer Canada to attend meetings; and has received speaker fees from Novartis and Pfizer Canada.
- **Dr. Chris MacKnight** has served on the board of the Alzheimer Society of Nova Scotia; has received speaker fees from Janssen-Ortho, Pfizer Canada, Novartis and Lundbeck Canada; and has received research grants from Janssen-Ortho, Pfizer Canada, Novartis, Lundbeck Canada, Voyager Pharmaceuticals, Myriad and Neurochem.
- **Dr. Fadi Massoud** has served on the advisory boards of Janssen-Ortho, Lundbeck Canada, Novartis and Pfizer; and has received speaker fees for CME presentations as well as research grants from these companies.
- **Dr. Ziad Nasreddine** has served as a consultant, adviser and program organizer for Pfizer Canada and an adviser to Novartis and Janssen-Ortho; has received lecture fees from Pfizer, Novartis and Janssen-Ortho; and has received research grants from Novartis, Janssen-Ortho, Neurochem, Myriad and Sanofi-Aventis.
- **Dr. Alain Robillard** has served on the advisory boards of and as a consultant to Pfizer Canada, Novartis, Janssen-Ortho and Lundbeck Canada; has received speaker fees from Pfizer Canada, Novartis, Janssen-Ortho and Lundbeck Canada; and has served as an investigator on studies funded by Pfizer Canada, Novartis, Janssen-Ortho, Lundbeck Canada, Sanofi-Aventis, GlaxoSmithKline, Myriad, Ono, Neurochem, Voyager, Elan and Wyeth.
- **Dr. Kenneth Rockwood** has served on the advisory boards of Pfizer Canada, Janssen-Ortho and Lundbeck Canada; has served as a consultant to Pfizer Canada, Janssen-Ortho, Novartis and the Nova Scotia Department of Health; has received speaker fees from Pfizer Canada, Novartis and Merck Frosst; has received research grants from Janssen-Ortho, the Canadian Institutes of Health Research (CIHR) and the Alzheimer Society of Canada; has received career awards from the CIHR and the Dalhousie Medical Research Foundation; and is President and majority shareholder of DementiaGuide, Inc.
- **Dr. A. Dessa Sadovnick** has received speaker fees from Biogen Idec, Serono, Teva Neuroscience and Berlex Canada; has received honoraria from these companies to attend meetings; and has received funding for research into multiple sclerosis from Teva Neuroscience and Berlex Canada.
- **Dr. Hyman Schipper** has served as a consultant to Caprion Pharmaceuticals and Osta Biotechnologies; was a founding scientist of and holds equity in Molecular Biometrics, LLC.

^{*}Participants who did not declare any competing interests are not included in this list.